| Knox, Jennifer |
| Active, not recruiting | 3 | 908 | Europe, Canada, Japan, US, RoW | Durvalumab, IMFINZI, Bevacizumab, AVASTIN, Placebo | AstraZeneca, AstraZeneca AB | Hepatocellular Carcinoma | 05/26 | 05/27 | | |
|
|
| Active, not recruiting | 2 | 150 | Canada, US | Folfirinox, Folinic Acid/Leucovorin, 5-Fluouracil, Irinotecan, Oxaliplatin, Gemcitabine/nab-paclitaxel | University Health Network, Toronto, Johns Hopkins University, Cold Spring Harbor Laboratory, Ontario Institute for Cancer Research, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Stand Up To Cancer | Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Cancer | 01/25 | 09/26 | | |
| Recruiting | 2 | 20 | Canada | Cabozantinib, CABOMETYX | University Health Network, Toronto, Ipsen | Hepatocellular Carcinoma, Recurrent Cancer, Liver Transplant | 08/25 | 12/25 | | |
NCT02151084: A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer |
|
|
| Active, not recruiting | 2 | 57 | Canada | Selumetinib, AZD6244, Cisplatin, Platinol, Gemcitabine, Gemzar | University Health Network, Toronto | Biliary Tract Carcinoma, Gallbladder Carcinoma | 12/24 | 12/25 | | |
| Active, not recruiting | 2 | 19 | Canada | Pembrolizumab, KEYTRUDA, Stereotactic Body Radiotherapy (SBRT) | University Health Network, Toronto | Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| Recruiting | 2 | 28 | Europe, Canada | Tremelimumab, Durvalumab | University Health Network, Toronto, Clinica Universidad de Navarra, Universidad de Navarra, University of Milan | Hepatocellular Carcinoma | 11/25 | 11/26 | | |
| Recruiting | 2 | 70 | Canada | Neoadjuvant | Ontario Clinical Oncology Group (OCOG), Hoffmann-La Roche | Hepatocellular Carcinoma, Portal Vein Tumour Thrombosis | 06/26 | 06/26 | | |
| Terminated | 1/2 | 6 | Canada | SLC-0111, WBI-5111, Gemcitabine Injection, Gemcitabine | British Columbia Cancer Agency, Canadian Cancer Society (CCS), SignalChem Lifesciences Corporation | Metastatic Pancreatic Ductal Adenocarcinoma | 05/24 | 05/24 | | |
COMPASS, NCT02750657: Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection |
|
|
| Active, not recruiting | N/A | 332 | Canada | Molecular Profiling | University Health Network, Toronto | Carcinoma, Pancreatic Ductal | 12/24 | 12/24 | | |
NeoPancOne, NCT04472910: GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma |
|
|
| Active, not recruiting | N/A | 84 | Canada | Modified Folforinox (mFFX), Folfirinox or other approach | University Health Network, Toronto, Pancreatic Cancer Canada | Resectable Pancreatic Cancer | 12/25 | 12/25 | | |
| Rusconi, Stefano |
| Not yet recruiting | 3 | 4000 | Europe | Baricitinib Oral Tablet [Olumiant], Olumiant, Remdesivir, Veklury, Dexamethasone | ASST Fatebenefratelli Sacco, AIFA | Covid19 | 03/22 | 12/22 | | |
| Recruiting | 3 | 440 | Europe | DOVATO, dolutegravir/lamivudine | Societa' Italiana Di Malattie Infettive E Tropicali | HIV-1-infection | 04/23 | 04/24 | | |
| Completed | 3 | 447 | Europe | Biktarvy, Symtuza | NEAT ID Foundation, Gilead Sciences, Janssen Pharmaceuticals | HIV/AIDS | 06/24 | 06/24 | | |
| Terminated | 2/3 | 28 | Europe, RoW | Fostamatinib, Placebo | NEAT ID Foundation, National Institutes of Health (NIH) | COVID-19, SARS-CoV2 Infection, Coronavirus Infection | 12/23 | 12/23 | | |
| Cozzolino, Mario |
| Terminated | 3 | 667 | Europe, Japan, US, RoW | Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule | Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC | Autosomal Dominant Polycystic Kidney, ADPKD | 08/23 | 08/23 | | |
| PEYVANDI, Flora |
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) |
|
|
| Recruiting | 3 | 34 | Europe, US, RoW | von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Von Willebrand Disease | 01/25 | 01/25 | | |
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial |
|
|
| Recruiting | 3 | 150 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor | 11/28 | 11/28 | | |
NCT05714969 / 2022-001940-36: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) |
|
|
| Active, not recruiting | 2 | 40 | Europe, US, RoW | TAK-755, rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930 | Takeda, Takeda Development Center Americas, Inc. | Thrombotic Thrombocytopenic Purpura (TTP) | 03/25 | 03/25 | | |
| Active, not recruiting | 2 | 3 | Europe, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia B with Inhibitor, Hemophilia B | 11/24 | 02/25 | | |
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B |
|
|
| Active, not recruiting | 2 | 60 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B | 11/24 | 02/25 | | |
| Recruiting | N/A | 300 | Europe | Whole-exome sequencing | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Low Von Willebrand Factor | 10/22 | 05/23 | | |
| Recruiting | N/A | 132 | Europe | | Fondazione Luigi Villa | TTP - Thrombotic Thrombocytopenic Purpura | 05/30 | 05/30 | | |
| Terminated | N/A | 108 | Europe, Canada, US, RoW | No Intervention | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia A, Hemophilia B | 11/24 | 11/24 | | |
| Recruiting | N/A | 100 | Europe, Canada, US, RoW | | Indiana Hemophilia &Thrombosis Center, Inc., Fondazione Angelo Bianchi Bonomi | Plasminogen Deficiency | 03/27 | 04/27 | | |
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A |
|
|
| Active, not recruiting | N/A | 207 | Europe, US, RoW | ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855 | Baxalta now part of Shire | Hemophilia A | 02/30 | 02/30 | | |
| Elli, Luca |
| Completed | 2 | 153 | Europe, Canada, US | TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar | Takeda | Celiac Disease | 11/24 | 11/24 | | |
FODMAP2019, NCT04655495: Impact of a Low-FODMAP Gluten-free Diet on Gut Microbiota and Circulating miRNAs in Celiac Disease Patients |
|
|
| Recruiting | N/A | 30 | Europe | Low FODMAPs /balanced gluten free diet | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Celiac Disease | 01/23 | 01/23 | | |
NCT05066191: Impact of Gluten Contamination in Celiac Patients Clinically Responsive and Unresponsive to the Gluten-free Diet |
|
|
| Recruiting | N/A | 300 | Europe | | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Celiac Disease | 02/22 | 03/22 | | |
MICI2021, NCT05079932: Pilot Study for the Evaluation of Food Choices in Patients With Inflammatory Bowel Diseases |
|
|
| Recruiting | N/A | 45 | Europe | | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Inflammatory Bowel Diseases | 04/23 | 05/24 | | |
| Rasperini, Giulio |
NCT06100120: A Triple-blinded Non-inferiority Multicentre Randomized Controlled Trial Comparing Hybrid and Fully Etched Implants P1 |
|
|
| Recruiting | N/A | 128 | Europe | Implant placement | University of Milan | Dental Implants | 11/24 | 01/25 | | |
| Chiapasco, Matteo |
NCT04480073: Guided Bone Regeneration With Customized Titanium Meshes |
|
|
| Recruiting | N/A | 24 | Europe | Customized CAD-CAM Titanium Mesh (Y-xoss CBR® by Reoss -Filderstadt - Germany) for Guided Bone Regeneration of atrophic alveolar ridges | University of Milan | Bone Resorption | 12/21 | 12/22 | | |
| Branchi, Federica |
| Completed | 2 | 38 | Europe, RoW | TPM502, Placebo | Topas Therapeutics GmbH, Topas Therapeutics GmbH | Celiac Disease | 07/24 | 07/24 | | |
| Vignoli, Aglaia |
| Recruiting | N/A | 20 | Europe | alpha-lactalbumin, fructooligosaccharides, inulin, alpha-lactalbumin, sodium butyrate, fructooligosaccharides, inulin | University of Milan, Fondazione Telethon, Kolfarma s.r.l. - Italy | CDKL5 | 01/25 | 04/25 | | |
| Colombo, Carla |
| Completed | N/A | 50 | Europe | linoleic acid supplementation, oleic acid supplementation | Karolinska Institutet, European Society of Pediatric Gastroenterology, Hepatology and Nutrition | Cystic Fibrosis | 10/24 | 11/24 | | |
| Recruiting | N/A | 250 | Europe | | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Cystic Fibrosis | 05/24 | 05/24 | | |
| Lodi, Giovanni |
NCT04858100: Oral Potentially Malignant Disorders: Comparison Between Surgical Treatment and Wait and See Approach |
|
|
| Recruiting | N/A | 310 | Europe | Surgical excision of the lesion, Wait and see approach | University of Milan | Leukoplakia, Oral | 03/26 | 03/26 | | |
| Cetin, Irene |
| Recruiting | N/A | 2550 | Europe | | University of Milano Bicocca | Low-Lying; Placenta, Hemorrhage, Complicating Delivery | 10/24 | 04/25 | | |
| Lombardo, Vincenza |
FODMAP2019, NCT04655495: Impact of a Low-FODMAP Gluten-free Diet on Gut Microbiota and Circulating miRNAs in Celiac Disease Patients |
|
|
| Recruiting | N/A | 30 | Europe | Low FODMAPs /balanced gluten free diet | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Celiac Disease | 01/23 | 01/23 | | |
| Carbone, Floriana |
NCT06308172: Impact of Single- Versus Double-layer Hysterotomy Closure on Cesarean Niche Development: a Randomized Controlled Trial |
|
|
| Recruiting | N/A | 150 | Europe | Hysterotomy closure | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Cesarean Section; Dehiscence, Uterine Bleeding, Uterus; Scar, Uterus Abnormal, Cesarean Section Complications | 12/24 | 12/26 | | |
| Morad, Yair |
| Recruiting | N/A | 75 | Europe, Canada, US, RoW | Patching, Prism Adaptation | University of Rochester | Exotropia | 07/25 | 07/25 | | |
| Nucci, Paolo |
| Recruiting | N/A | 75 | Europe, Canada, US, RoW | Patching, Prism Adaptation | University of Rochester | Exotropia | 07/25 | 07/25 | | |
| Mazaferro, Vincenzo |
| Recruiting | 2 | 28 | Europe, Canada | Tremelimumab, Durvalumab | University Health Network, Toronto, Clinica Universidad de Navarra, Universidad de Navarra, University of Milan | Hepatocellular Carcinoma | 11/25 | 11/26 | | |
| Arduino, Paolo |
NCT04858100: Oral Potentially Malignant Disorders: Comparison Between Surgical Treatment and Wait and See Approach |
|
|
| Recruiting | N/A | 310 | Europe | Surgical excision of the lesion, Wait and see approach | University of Milan | Leukoplakia, Oral | 03/26 | 03/26 | | |
| Martini, Daniela |
| Not yet recruiting | N/A | 50 | Europe | MD high in UPF, MD low in UPF | University of Milan, University of Florence, University of Teramo | Overweight | 10/24 | 06/25 | | |
